TY - JOUR
T1 - Roflumilast, a Type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis
AU - Maiga, Mariama C.
AU - Ahidjo, Bintou Ahmadou
AU - Maiga, Mamoudou
AU - Bishai, William R.
N1 - Funding Information:
This work was supported by National Institutes of Health (NIH) grants A1079590, AI37856, and AI36973 (W.R.B), by the NIH, NIAID Division of Intramural Research (M.M.), and by the Howard Hughes Medical Institute (W.R.B). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Publisher Copyright:
© 2015, American Society for Microbiology. All Rights Reserved.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT).
AB - With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. Alone, roflumilast had no effect on lung bacillary burden and mortality. However, when roflumilast was used in combination with isoniazid, a reduction in lung bacillary burden was observed. These data suggest that roflumilast may be a good candidate for tuberculosis host-directed therapy (HDT).
UR - http://www.scopus.com/inward/record.url?scp=84954570108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954570108&partnerID=8YFLogxK
U2 - 10.1128/AAC.02145-15
DO - 10.1128/AAC.02145-15
M3 - Article
C2 - 26438491
AN - SCOPUS:84954570108
SN - 0066-4804
VL - 59
SP - 7888
EP - 7890
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 12
ER -